About WellGen
WellGen is a company based in North Brunswick (United States) founded in 1997. WellGen has raised $12.5 million across 2 funding rounds from investors including Amphion Innovations. WellGen operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter North Brunswick, United States
- SectorsHealthcare
- Website wellgen.com
- Social LinkedIn
- Legal Name Wellgen, Inc.
- Total Equity Funding$12.5M (USD)
in 2 rounds
- Latest Funding Round$9.5M (USD), Series C
Oct 2007
- Investors
Funding Insights of WellGen
WellGen has successfully raised a total of $12.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $9.5 million completed in October 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.5M
- Total Rounds 2
- Last Round Series C — $9.5M
- First Round $3M
(Feb 2006)
- Investors Count 1
All 2 funding rounds of WellGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2007 | $9.5M | Series C | – | – | |
| Feb 2006 | $3M | Series B | – | – |
1 investors in total: 1 institutional.
Investors in WellGen
WellGen has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Amphion Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech and life sciences focused VC firm investing in geographies such as the US and the UK | 1984 | amphionplc.com | New York, United States |
Investor details for WellGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of WellGen
3 dated milestones of WellGen across 10 years, from founding to its latest funding, stage changes and deals.
- Founded WellGen is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series C, of $9.5M.
Competitors of WellGen
WellGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| editasmedicine.com | 2013 | Cambridge, United States | $210M | 257 | Therapeutics for rare genetic diseases are developed using CRISPR technology. |
Detailed competitors of WellGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Wellgen
Complete news archive for WellGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to WellGen
10 companies that operate in the same segment as WellGen (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about WellGen
WellGen was founded in 1997 and raised its 1st funding round 9 years after it was founded.
WellGen is headquartered in North Brunswick, United States. It is registered at North Brunswick, New Jersey, United States.
WellGen is a funded company, having raised a total of $12.5M across 2 funding rounds to date. The company's 1st funding round was a Series B of $3M, raised on Feb 2006.
Founded in 1997, WellGen operates in the nutrigenomics sector from North Brunswick, United States. Proprietary medical foods are created through in-house expertise in natural product chemistry and gene expression analysis. The Alignomxa bioinformatics model is utilized to identify optimal therapeutic areas for a pipeline of natural products. Opportunities in functional foods, beverages, and dietary supplements are also pursued.
WellGen's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
WellGen has 1 investor. Key investors include Amphion Innovations.
WellGen operates through Wellgen, Inc..